Navigation Links
Roy Castle lung cancer research funding
Date:3/12/2014

LIVERPOOL, UK 12 March 2014: The Roy Castle Lung Cancer Foundation has funded two new projects at the University of Liverpool which aim to improve survival rates for the UK's biggest cancer killer.

Professor John Field, a Clinical Professor of Molecular Oncology, will receive 200,000 for the Liverpool Lung Project (LLP). The Roy Castle Lung Cancer Foundation has invested 20m over 23 years into lung cancer research, including funding the Liverpool Lung Project for 18 years. The LLP is now recognised internationally as one of the major lung cancer cohort studies, which has made very significant contributions to early lung cancer research.

The Liverpool Lung Project is the largest of its kind in Europe with over 12,000 participants. The information for this large study has provided a method of identifying high risk individuals for further investigations. This included the LLP Risk Model which has been utilised in the recent UK Lung Cancer CT screening trial.

The LLP research programme focuses on Liverpool, as it has the most cases of lung cancer in the country and the wide range of valuable specimens has enabled the discovery and validation of a number of early lung cancer diagnostic biomarkers.

Researchers recruit people who are attending hospital for tests, as well as people who have recently been diagnosed with lung cancer and ask them to complete a short lifestyle questionnaire. They are also asked to give a blood sample, a swab from inside their mouth and, in some cases, a tissue sample. The information and samples are then used to help to identify groups of people who are at a high risk of developing lung cancer.

Professor Field said: "The Roy Castle Lung Cancer Foundation has provided the means to develop and implement early lung cancer detection techniques which would have been impossible without their support. Their investment in the Liverpool Lung Project has made a major impact on lung cancer research nationally and internationally, for which we are extremely grateful."

In the second project, molecular oncologist, from the University's Institute of Translational Medicine, Dr Lakis Liloglou, will receive 75k to look for genetic markers in a patient's blood which could identify lung cancer at a very early stage, when it can still be cured.

He has previously identified similar genetic markers by taking samples, called bronchial washings, from patients' airways, which is a complex clinical procedure.

Dr Liloglou's research team will now try to find the same markers in a patient's blood, leading to a cheap and simple blood test to diagnose lung cancer at a very early stage.

Despite being the biggest killer, lung cancer receives only 7% of cancer research funding. Consultant oncologist David Gilligan is head of the charity's grants committee. He said: "There is only 425 spent on research for every person who dies from lung cancer compared to 3,509 for breast cancer, which is one of the reasons breast cancer has much higher survival rates.

"We are aiming to increase the amount of life-saving lung cancer research we are funding, but we cannot do it alone."


'/>"/>

Contact: Jamie Brown
jamie.brown@liverpool.ac.uk
44-151-794-2248
University of Liverpool
Source:Eurekalert

Related medicine news :

1. Home Care Assistance Opens New Office in Castle Rock, Colorado
2. Newcastle, Oklahoma High School Provides Football Team with Brain Sentry Impact Sensor, Helmet-Mounted Device Helps ID Players Who Need to be Evaluated for Concussion
3. Castle Baths Launches Two New Tre’Yours Products, Men’s and Women’s Spa Lines
4. Minimally Invasive Spinal Surgeon, Dr. Michael A. Gleiber of South Florida, is selected to Castle Connolly's Top Doctors List for 2013
5. UV light aids cancer cells that creep along the outside of blood vessels
6. Several FDA-approved anti-cancer drugs induce stem cell tumors, perhaps thwarting therapy
7. New sugar-test to reduce false-positive cancer diagnoses
8. New high-tech glasses detect cancer cells during surgery
9. PSA-testing and early treatment decreases risk of prostate cancer death
10. Targeted drug may prolong survival of patients with cervical cancer
11. TGen and Scottsdale Healthcare cancer expert Dr. Daniel D. Von Hoff is honored by ASCO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... ... 09, 2016 , ... The Pennsylvania Athletic Trainers’ Society (PATS) ... summer of 2016. The program was made possible by a Pennsylvania Department of ... Health and Human Services Administration. The broadcast, Use Your Head: Properly Managing ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... Compensation Research Institute (WCRI) officially opened registration today for its 33rd Annual ... in Boston, MA . , The theme of the conference is “Persistent Challenges ...
(Date:12/8/2016)... PLAINS, N.Y., and JENNERSVILLE, Pa. (PRWEB) , ... ... ... to announce that Penn Medicine Southern Chester County, a Property owned by an ... The $23 million, 72,000 square foot Penn Medicine Southern Chester County ambulatory care ...
(Date:12/8/2016)... , ... December 08, 2016 , ... With the increasing ... the “What’s In Your Mouth?” (WIYM) campaign to inform dentists and patients about the ... the dental implant and prosthetic market in the U.S. is projected to reach $6.4 ...
(Date:12/8/2016)... Tampa, Fla (PRWEB) , ... December 08, 2016 ... ... offering smarter modes of access for customers and employees that are both engaging ... ChangeGear 7 with Service Smart Technology, the software company revealed today its plans ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... 8, 2016  Eli Lilly and Company (NYSE: ... phase 3 EXPEDITION3 trial at the 9 th ... disclosed, solanezumab did not meet the primary endpoint in ... in people with mild dementia due to Alzheimer,s disease ... solanezumab for the treatment of mild dementia due to ...
(Date:12/8/2016)... Bodycad announced it has been awarded ... reproducibility and speed for 3D constructs via MRI ... orthopaedic applications. These patents are critical to the ... based on each patient,s distinct anatomy. ... the world,s first suite of orthopaedic CAD/CAM software. ...
(Date:12/8/2016)... , Dec. 8, 2016  EIP Pharma, ... has obtained proof-of-mechanism for neflamapimod (previously code named ... Phase 2a clinical trials that demonstrated significant Alzheimer,s ... 302 (12-week treatment) and Study 303 (6-week treatment) ... Trials in Alzheimer,s Disease (CTAD) scientific conference in ...
Breaking Medicine Technology: